Cure TV

For Ashliann Mazeika, a diagnosis at 24 led to a decade-long treatment journey affirmed by the Breast Cancer Index test.

Dr. Anne Peled co-developed the sensation-preserving mastectomy she received after her second diagnosis of breast cancer.

For Richard “Rocky” Kimball, a diagnosis of myelodysplastic syndromes, or MDS, necessitated a number of lifestyle changes.

Dr. Nicholas Hornstein explained the concept of ctDNA and how this blood test may help guide treatment decisions, including whether additional therapy is needed.

CURE spoke with Dr. Robert Alter of John Theurer Cancer Center about the best time to explore clinical trials.

Dr. William A. Hall sat down with CURE to discuss the impact of technologies like artificial intelligence on gastrointestinal cancer care.

CURE sat down with Dr. Surbhi Sidana to discuss this treatment combination.

At Keck Medicine of USC, surgeons, oncologists and radiation specialists collaborate closely, ensuring individualized care for patients with lung cancer.

Dr. Elena Elimova discussed data showing 21-month progression-free survival with Ziihera, Tevimbra and chemotherapy for some patients.

Dr. Benjamin Jon Golas explains that surgery, chemotherapy and radiation form the foundation of curative-intent treatment for patients with pancreas cancer.

Dr. Nadine A. Jackson explains how relatively simple interventions may help close gaps in access to genomics-driven trials across gastrointestinal cancers.

Dr. Ian Flinn explains how Lunsumio VELO works, offering an outpatient immunotherapy option with accelerated FDA approval.

Tukysa may be a patient-friendly option as a first line maintenance treatment for HER2-positive breast cancer, as Dr. Erika Hamilton explained.

Dr. Thejus Jayakrishnan discussed how patients and physicians weigh treatment options in later-line metastatic colorectal cancer.

Dr. Elena Elimova discusses how Ziihera-based therapy may change treatment for HER2+ locally advanced or metastatic gastroesophageal adenocarcinoma.

Dr. William A. Hall discusses overtreatment in gastrointestinal cancer care and how AI-driven response assessment is shaping personalized treatment.

Dr. Erika Hamilton spoke with CURE’s editor-in-chief, Dr. Joshua K. Sabari.

Dave Coulier sat down for an interview with CURE to discuss his recent tongue cancer diagnosis and his treatment journey.

Dr. Vinayak Venkataraman sat down for an interview with CURE to discuss the evolving treatment of gastrointestinal stromal tumors.

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy played in her care.

Prostate cancer survivors Ronald Wakefield and Ernie Strauss sat down for an interview with CURE.

Dave Coulier, who has become a vocal advocate during his cancer journeys, has launched a digital wellness platform, AwearMarket.

Wendy Brooks, a survivor of extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, highlight the role of self-advocacy.

Dan, a pancreatic cancer survivor and advocate, shared insights on participating in clinical trials and the importance of self-advocacy.

Oya Gilbert, diagnosed with multiple myeloma in 2017, advises patients to bring someone to appointments, ask questions and seek second opinions.

CURE spoke with an expert about why a support system is crucial for patients with lung cancer.

CURE was on site at the 2025 ASH Annual Meeting, sharing expert conversations and patient-focused reporting that highlighted progress in blood cancer care.

Jace Yawnick explained why a support system is essential for patients with cancer.